A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease
Authors:
- Kwang Woo KimKKKwang Woo Kim
- Hyoun Woo KangHKHyoun Woo Kang
- Seong-Joon KohSKSeong-Joon Koh
- Hyuk YoonHYHyuk Yoon
- Sihyun KimSKSihyun Kim
- Yukyung JunYJYukyung Jun
- Hyun Jung LeeHLHyun Jung Lee
- Jong Pil ImJIJong Pil Im
- Young Soo ParkYPYoung Soo Park
- Ji Won KimJKJi Won Kim
- Joo Sung KimJKJoo Sung Kim
- Seoul National University Inflammatory Bowel Disease Research Network (SIRN)S(Seoul National University Inflammatory Bowel Disease Research Network (SIRN)
Open Access
- 31 October 2025
- journal article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 483-490
Abstract
Background/Aims: We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD). Methods: This retrospective, multicenter, observational study enrolled patients treated with either intravenous or subcutaneous IFX. Sequential parameters were compared at baseline, 6 months, and 12 months following the initiation of treatment with either type of IFX. The primary outcome was the comparison of the IFX trough levels after 12 months of treatment.Results: In total, 183 participants were included in this study. After 6 months, the subcutaneous group exhibited significant differences compared to the intravenous group; in terms of clinical disease activity (0% vs. 15%, P= 0.007) and IFX trough level (21.72 ± 8.71 μg/mL vs. 7.70 ± 16.65 μg/mL, P= 0.002). After 12 months, subcutaneous, as compared to intravenous, achieved improved clinical disease activity (0% vs. 15%, P= 0.044) and IFX trough level (20.41 ± 12.91 μg/mL vs. 7.06 ± 6.81 μg/mL, P< 0.001). Analyzing the sequential changes compared with baseline data within each group, we observed significant alterations in subcutaneous; 6 months fecal calprotectin (676.3 ± 976.6 μg/g vs. 253.9 ± 483.9 μg/g, P= 0.014), 6 months IFX trough level (7.00 ± 5.67 μg/mL vs. 18.44 ± 6.34 μg/mL, P= 0.026), and 12 months IFX trough level (7.00 ± 5.67 μg/mL vs. 21.33 ± 4.50 μg/mL, P= 0.034).Conclusions: This study indicates the potential suitability of subcutaneous IFX as an alternative treatment option for IBD.Keywords
Funding Information
- National Research Foundation of Korea (2022R1F1A1076019, RS-2023-00227939, 2021R1F1A1062000, 2022M3A9F3017371)
- Ministry of Science and ICT
- Seoul Metropolitan Government Seoul National University Boramae Medical Center (04-2023-0012)
- CELLTRION PHARM, Inc. (CR 2022-2)
- Seoul National University Hospital
This publication has 28 references indexed in Scilit:
- Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH StudyClinical Gastroenterology and Hepatology, 2022
- Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical BenefitClinical Drug Investigation, 2022
- Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future PerspectivesGastroenterology, 2022
- Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseGastroenterology, 2021
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2019
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority studyThe Lancet, 2019
- Management of loss of response to anti-TNF drugs: Change the dose or change the drug?Journal of Crohn's and Colitis, 2008
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Development of a Crohn's Disease Activity IndexGastroenterology, 1976